187 related articles for article (PubMed ID: 38704569)
21. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
22. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria.
Renard D; Castelnovo G; Wacongne A; Le Floch A; Thouvenot E; Mas J; Gabelle A; Labauge P; Lehmann S
J Neurol; 2012 Nov; 259(11):2429-33. PubMed ID: 22576334
[TBL] [Abstract][Full Text] [Related]
23. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis.
Charidimou A; Friedrich JO; Greenberg SM; Viswanathan A
Neurology; 2018 Feb; 90(9):e754-e762. PubMed ID: 29386280
[TBL] [Abstract][Full Text] [Related]
24. Cerebral Amyloid Angiopathy Is Associated With Executive Dysfunction and Mild Cognitive Impairment.
Case NF; Charlton A; Zwiers A; Batool S; McCreary CR; Hogan DB; Ismail Z; Zerna C; Coutts SB; Frayne R; Goodyear B; Haffenden A; Smith EE
Stroke; 2016 Aug; 47(8):2010-6. PubMed ID: 27338926
[TBL] [Abstract][Full Text] [Related]
25. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
[TBL] [Abstract][Full Text] [Related]
26. Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease.
Carmona-Iragui M; Balasa M; Benejam B; Alcolea D; Fernández S; Videla L; Sala I; Sánchez-Saudinós MB; Morenas-Rodriguez E; Ribosa-Nogué R; Illán-Gala I; Gonzalez-Ortiz S; Clarimón J; Schmitt F; Powell DK; Bosch B; Lladó A; Rafii MS; Head E; Molinuevo JL; Blesa R; Videla S; Lleó A; Sánchez-Valle R; Fortea J
Alzheimers Dement; 2017 Nov; 13(11):1251-1260. PubMed ID: 28463681
[TBL] [Abstract][Full Text] [Related]
27. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
[TBL] [Abstract][Full Text] [Related]
28. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
van Waalwijk van Doorn LJC; Ghafoorian M; van Leijsen EMC; Claassen JAHR; Arighi A; Bozzali M; Cannas J; Cavedo E; Eusebi P; Farotti L; Fenoglio C; Fortea J; Frisoni GB; Galimberti D; Greco V; Herukka SK; Liu Y; Lleó A; de Mendonça A; Nobili FM; Parnetti L; Picco A; Pikkarainen M; Salvadori N; Scarpini E; Soininen H; Tarducci R; Urbani A; Vilaplana E; Meulenbroek O; Platel B; Verbeek MM; Kuiperij HB
J Alzheimers Dis; 2021; 79(1):163-175. PubMed ID: 33252070
[TBL] [Abstract][Full Text] [Related]
29. Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults.
Kresge HA; Liu D; Gupta DK; Moore EE; Osborn KE; Acosta LMY; Bell SP; Pechman KR; Gifford KA; Mendes LA; Wang TJ; Blennow K; Zetterberg H; Hohman TJ; Jefferson AL
J Alzheimers Dis; 2020; 74(3):965-974. PubMed ID: 32144980
[TBL] [Abstract][Full Text] [Related]
30. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij BH; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
[TBL] [Abstract][Full Text] [Related]
31. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid profiles with increasing number of cerebral microbleeds in a continuum of cognitive impairment.
Shams S; Granberg T; Martola J; Li X; Shams M; Fereshtehnejad SM; Cavallin L; Aspelin P; Kristoffersen-Wiberg M; Wahlund LO
J Cereb Blood Flow Metab; 2016 Mar; 36(3):621-8. PubMed ID: 26661151
[TBL] [Abstract][Full Text] [Related]
33. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
34. Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression.
Jahn T; Clark C; Kerksiek A; Lewczuk P; Lütjohann D; Popp J
J Steroid Biochem Mol Biol; 2021 Jan; 205():105785. PubMed ID: 33171206
[TBL] [Abstract][Full Text] [Related]
35. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.
Twohig D; Rodriguez-Vieitez E; Sando SB; Berge G; Lauridsen C; Møller I; Grøntvedt GR; Bråthen G; Patra K; Bu G; Benzinger TLS; Karch CM; Fagan A; Morris JC; Bateman RJ; Nordberg A; White LR; Nielsen HM;
Acta Neuropathol Commun; 2018 Nov; 6(1):130. PubMed ID: 30477568
[TBL] [Abstract][Full Text] [Related]
36. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M
Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
[TBL] [Abstract][Full Text] [Related]
37. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.
Geijselaers SLC; Aalten P; Ramakers IHGB; De Deyn PP; Heijboer AC; Koek HL; OldeRikkert MGM; Papma JM; Reesink FE; Smits LL; Stehouwer CDA; Teunissen CE; Verhey FRJ; van der Flier WM; Biessels GJ;
J Alzheimers Dis; 2018; 61(1):309-320. PubMed ID: 29154275
[TBL] [Abstract][Full Text] [Related]
38. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
39. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
40. Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias.
Geng C; Tan L; Chen C
Brain Res; 2024 Jun; 1833():148881. PubMed ID: 38519009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
